GlaxoSmithKline has been partnering with Brazil’s Oswaldo Cruz Foundation (FioCruz) since 1985 to manufacture vaccines for public health priorities in Brazil including polio, Haemophilus influenzae type b (Hib), measles, mumps, rubella, rotavirus and, most recently, pneumococcal disease.
To address pneumococcal disease in Brazil, GlaxoSmithKline will provide FioCruz with access to the technology behind its SynflorixTM vaccine which protects against life-threatening pneumonia, meningitis and bacteraemia infections. GlaxoSmithKline will supply SynflorixTM to FioCruz until the technology transfer is completed. The deal benefits both GlaxoSmithKline and FioCruz and is helping to ensure that the annual cohort of 3.5 million babies in Brazil will be protected by GlaxoSmithKline's and Fiocruz vaccines.
|Location||Latin America and Caribbean, Brazil|